Cyclosporine A Delays the Terminal Disease Stage in the Tfam KO Mitochondrial Myopathy Mouse Model Without Improving Mitochondrial Energy Production.
Abstract
Mitochondrial myopathies are rare genetic disorders for which no effective treatment exists. We previously showed that the pharmacological cyclophilin inhibitor cyclosporine A (CsA) extends the lifespan of fast-twitch skeletal muscle-specific mitochondrial transcription factor A knockout (Tfam KO) mice, lacking the ability to transcribe mitochondrial DNA and displaying lethal mitochondrial myopathy. Our present aim was to assess whether the positive effect of CsA was associated with improved in vivo mitochondrial energy production.
The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.
Research summary
The paper investigates the effects of cyclosporine A on a specific mitochondrial myopathy mouse model, which is related to mitochondrial dysfunction—a key aspect of aging. However, the study does not address the root causes of aging or propose a mechanism for lifespan extension; rather, it focuses on delaying disease progression without improving mitochondrial energy production. This limits its overall impact on the field of longevity research, making it a solid but not groundbreaking contribution.
Author of this paper? Send a correction.